Abstract Background: This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab. Methods: Laboratory abnormalities and adverse events of hypocalcaemia in patients with metastatic bone disease were analysed using data from three identically designed phase 3 trials of subcutaneous denosumab 120 mg (n = 2841) versus intravenous zoledronic acid 4 mg (n = 2836). Results: The overall incidence of laboratory events of hypocalcaemia grade P2 was higher with denosumab (12.4%) than with zoledronic acid (5.3%). Hypocalcaemia events were primarily grade 2 in severity and usually occurred within the first 6 months of treatment. Patients who reported taking calcium and/or vitamin D supplements had a lower incidence of hypocalcaemia. Prostate cancer or small-cell lung cancer, reduced creatinine clearance and higher baseline bone turnover markers of urinary N-telopeptide of type I collagen (uNTx; >50 versus 650 nmol/mmol) and bone-specific alkaline phosphatase (BSAP; >20.77 lg/L [median] versus 620.77 lg/L) values were important risk factors for developing hypocalcaemia. The risk associated with increased baseline BSAP levels was greater among patients who had >2 bone metastases at baseline versus those with 62 bone metastases at baseline. Conclusion: Hypocalcaemia was more frequent with denosumab versus zoledronic acid, consistent with denosumab's greater antiresorptive effect. Low serum calcium levels and potential vitamin D deficiency should be corrected before initiating treatment with a potent osteoclast inhibitor, and corrected serum calcium levels should be monitored during treatment. Adequate calcium and vitamin D intake appears to substantially reduce the risk of hypocalcaemia.
Introduction
Many patients with malignancies develop bone metastases during disease progression [1] [2] [3] . Bone metastases disrupt the normal homeostasis between bone formation and resorption by promoting osteoclast maturation and activity and increased bone resorption [1] . The shift toward increased bone resorption may result in bone destruction and skeletal-related events (SREs), such as pathologic fracture, spinal cord compression, severe pain and the need for skeletal radiation or surgery [1] .
Antiresorptive agents used to treat bone metastases inhibit osteoclastic bone resorption and reduce skeletal calcium release into circulation. Hypocalcaemia has been observed with oral and intravenous bisphosphonates and the receptor activator of nuclear factor-kappa b ligand (RANKL) inhibitor denosumab [1, [4] [5] [6] [7] . Risk factors for hypocalcaemia include osteoblastic metastases [8, 9] or extensive osteoid, as in osteomalacia [10] , both of which may act as a calcium sink. Low baseline serum calcium concentrations [11] and concurrent corticosteroids [11] have also been associated with hypocalcaemia on antiresorptive therapy.
A combined analysis of three phase 3 trials in patients with metastatic bone disease showed denosumab was superior to zoledronic acid (ZA) in preventing SREs [5] . The overall safety profiles of denosumab and ZA were generally similar; however, hypocalcaemia was more frequent with denosumab [5] . This retrospective analysis assessed hypocalcaemia based on laboratory abnormalities and clinical evaluations collected during these trials to further identify and characterise potential risk factors.
Patients and methods

Patients
This retrospective analysis included patient-level data from three identically designed, double-blind, double-dummy, international phase 3 trials comparing the efficacy and safety of denosumab versus ZA for the prevention of SREs in patients with metastatic bone disease and advanced breast cancer (NCT00321464) [12] , prostate cancer (NCT00321620) [13] , or other solid tumours or multiple myeloma (NCT00330759) [14] . Details of the study designs and results are published [5, [12] [13] [14] . Patients provided written informed consent; the study protocols were approved by each site's ethics committee.
Study design and treatment
Patients received either subcutaneous denosumab 120 mg (plus intravenous placebo) or intravenous infusion of ZA 4 mg (plus subcutaneous placebo) every 4 weeks. ZA dosing was adjusted for renal impairment per the label and withheld as needed for renal insufficiency. Daily calcium (P500 mg) and vitamin D (P400 IU equivalent) were strongly recommended for all patients; supplement intake was collected by patient report. Study treatment was withheld for any patient who experienced grade 3 or 4 hypocalcaemia (or any other adverse event [AE]) reported by the investigator as treatment related, and resumed when the event resolved to grade 61.
Study assessments
Serum calcium (albumin-corrected if albumin was <4 g/dL), measured every 4 weeks by a central laboratory, was analysed to identify hypocalcaemia. The incidence of laboratory hypocalcaemia by grade, defined by the Common Terminology Criteria for Adverse Events, version 3.0 [15] , was evaluated by treatment group.
Hypocalcaemia risk factors
Potential risk factors for hypocalcaemia that were evaluated were sex and race, calcium and/or vitamin D supplementation, baseline calculated creatinine clearance, tumour type, bone lesion type, length of exposure to study drug, baseline levels of bone-specific alkaline phosphatase (BSAP) and urinary N-telopeptide of type I collagen (uNTx), and number of bone metastases at baseline. Hypocalcaemia incidence was also summarised by baseline levels of calculated creatinine clearance (ie, 30-<60 mL/min, 60-<90 mL/min and P90 mL/min). The first occurrence of hypocalcaemia was evaluated by tumour type, time period and timing after dose.
Statistical analysis
The duration of the first occurrence of hypocalcaemia was calculated from the date of onset of hypocalcaemia grade P2 to the resolution date (AE) or to a lower grade of hypocalcaemia (laboratory values). The median duration of first occurrence of hypocalcaemia based on central laboratory results was estimated using the Kaplan-Meier method. The impact of on-study calcium/vitamin D supplement use on the risk of developing hypocalcaemia for denosumab-treated patients was evaluated using a time-dependent Cox proportional hazards model.
A Cox proportional hazards model was used to assess the baseline covariate significance of disease characteristics on the risk of developing grade P2 hypocalcaemia in univariate and multivariate analyses. Baseline characteristics with P < 0.05 from the univariate analyses were included in the multivariate model. The interactions of corrected uNTx and number of bone metastases, and BSAP and number of bone metastases, were explored using Cox proportional hazards models with the interaction term and the associated baseline covariates in the models separately.
Results
Baseline characteristics
Across the three trials, patients were randomised to denosumab (n = 2862) or ZA (n = 2861; Table 1 ). In both treatment groups, baseline characteristics were generally similar between patients who did and did not develop on-study hypocalcaemia. Overall, 2841 and 2836 patients in the denosumab and ZA groups, respectively, received P1 dose of study drug and were included in this analysis.
Incidence of hypocalcaemia
The incidence of laboratory-detected hypocalcaemia was higher for denosumab than for ZA overall and for each grade (Fig. 1A) . Similarly, the incidence of investigator-reported hypocalcaemia AEs was greater for denosumab than for ZA (Fig. 1B) . The majority of hypocalcaemia events were grade 2; no fatal hypocalcaemia events occurred during the trials.
Supplementation with calcium and/or vitamin D was associated with fewer hypocalcaemia AEs for both treatment groups (Fig. 1C and D) . With denosumab, the risk of developing an AE of hypocalcaemia was 40% lower among patients who reported taking supplements compared with those who did not (hazard ratio [HR] , 0.60 [95% confidence interval (CI), 0.45-0.81]; P = 0.0007). For ZA, the risk of developing hypocalcaemia was 27% lower for those who reported taking supplements compared with those who did not (HR, 0.73 [95% CI, 0.48-1.11]; P = 0.14).
First occurrence of hypocalcaemia
Hypocalcaemia occurred earlier for denosumabtreated than for ZA-treated patients. The median (Q1, Q3) time to first occurrence of hypocalcaemia grade P2 was 3.8 (1.8, 10.1) months with denosumab and 6.5 (2.2, 12.0) months with ZA. The median (Q1, Q3) time to first occurrence of hypocalcaemia grade P3 was longer in both groups: 4.6 (1.8, 12.6) and 7.8 (3.7, 13.8) months, respectively. The corresponding median (Q1, Q3) times to first occurrence of an AE of hypocalcaemia were 2.8 (1.0, 7.1) and 3.5 (1.0, 9.1) months.
Of the 353 denosumab-treated patients with hypocalcaemia grade P2, more than half had prostate cancer (Table 2 ). For most denosumab-treated patients and across all tumour types, the first occurrence of grade P2 hypocalcaemia or a hypocalcaemia AE was 66 months after initiating treatment (Table 2) ; 20.4% of denosumab-treated patients and 16.1% of ZA-treated patients experienced grade P2 hypocalcaemia between the first and second doses (Table 3) . Hypocalcaemia generally resolved by the next scheduled study visit. Using the beginning and end dates for the event-of-interest AEs to define duration, the first occurrence of hypocalcaemia lasted approximately a median of 3 weeks. Similarly, the Kaplan-Meier estimate of the median duration for first occurrence of hypocalcaemia was 30 days for denosumab and 29 days for ZA. Of the 502 patients who experienced grade P2 hypocalcaemia, 3 (0.6%) discontinued the study because of an AE of hypocalcaemia.
Most patients with hypocalcaemia experienced only one hypocalcaemic episode; 43% of denosumab-treated patients with hypocalcaemia and 32% of ZA-treated patients with hypocalcaemia had a recurrent event.
Among denosumab-treated patients, recurrence rates were highest for those with prostate cancer (94/943, 10%) and lowest for those with non-small-cell lung cancer (NSCLC; 3/345, 1%).
Factors associated with hypocalcaemia
In the denosumab-treated group, more men than women experienced grade P2 hypocalcaemia (15.4% versus 8.9%). The ZA-treated group did not show a difference based on sex (4.7% versus 5.8%). Neither treatment group showed differences based on race (Table 4) .
For each tumour type, the incidence of hypocalcaemia was higher with denosumab than ZA (Fig. 2) . Among denosumab-treated patients, those with prostate cancer or small-cell lung cancer (SCLC) had the highest incidence of hypocalcaemia. For patients receiving ZA, the incidence of hypocalcaemia was highest in those with SCLC or multiple myeloma. Those with NSCLC had the lowest incidence in both groups. The incidence of laboratory events of hypocalcaemia was higher in denosumab-treated patients with lower baseline values of creatinine clearance compared with those with higher values. In the denosumab-treated group, 15.5% of patients with baseline creatinine clearance 30 to <60 mL/min had a hypocalcaemia event, compared with 12.9% of those with values 60 to <90 mL/min and 11.0% of those with values P90 mL/min. The corresponding percentages in the ZA-treated group were 5.8% (30-<60 mL/min), 4.4% (60-<90 mL/min) and 5.8% (P90 mL/min).
The denosumab-treated patients who developed hypocalcaemia had higher baseline uNTx and BSAP levels than those who did not (Table 1) . Similarly, the ZA-treated patients who developed hypocalcaemia also had higher baseline uNTx levels than those who did not, although baseline BSAP levels were similar.
Covariate analyses of baseline characteristics showed several factors associated with risk of developing grade P 2 hypocalcaemia in denosumab-treated patients. In the univariate analysis, male sex, prostate cancer, SCLC, reduced creatinine clearance (30-<60 mL/min), higher baseline values of uNTx and BSAP, >2 bone metastases at baseline, interaction of baseline values of BSAP and the number of bone metastases, and osteoblastic lesions were significantly associated with an increased risk of developing hypocalcaemia (Table 4) .
In the multivariate analysis, an increased risk of developing hypocalcaemia was found for patients with prostate cancer or SCLC, reduced creatinine clearance (30-<60 mL/min) and higher baseline values of uNTx and BSAP (Table 4 ). The risk associated with increased baseline BSAP levels was greater among patients who also had >2 bone metastases at baseline versus patients with 62 bone metastases. Bone lesion type (osteolytic, osteoblastic, or mixed) at baseline did not increase the risk for developing hypocalcaemia (all P P 0.2697).
Discussion
Hypocalcaemia occurred more frequently in denosumab recipients than in ZA recipients, as measured by both laboratory values and AEs. The risk of developing hypocalcaemia AEs was 40% lower in denosumab-treated patients who reported taking calcium/vitamin D supplements. Univariate analysis identified several risk factors associated with the development NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer. BSAP, bone-specific alkaline phosphatase; CI, confidence interval; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; uNTx, urinary N-telopeptide of type I collagen.
a Univariate covariate analysis stratified by study. Only baseline characteristics with P < 0.05 from the univariate analyses were included in the multivariate model. of grade P2 hypocalcaemia, including male sex, prostate cancer or SCLC, reduced creatinine clearance, higher baseline values of uNTx and BSAP, >2 bone metastases at baseline, and osteoblastic lesions. In the multivariate analysis, risk factors associated with hypocalcaemia included prostate cancer or SCLC, reduced creatinine clearance and higher baseline values of uNTx and BSAP. Denosumab and ZA inhibit bone resorption by distinct mechanisms, and preclinical and clinical data indicate RANKL inhibitors are more potent at reducing bone turnover and destruction and the associated release of skeletal calcium than intravenous bisphosphonates [16, 17] . Importantly, the identified risk factors for hypocalcaemia with denosumab were similar to those previously ascribed to potent bisphosphonates, such as vitamin D deficiency, renal insufficiency and prostate cancer [18] [19] [20] . In our analysis, calcium and/or vitamin D supplementation at any time during denosumab therapy significantly lowered the risk of AEs of hypocalcaemia.
Previous analyses of hypocalcaemia in cancer patients treated with denosumab have relied primarily on clinical AE reports, which only include symptomatic hypocalcaemia events [21, 22] . Results from a meta-analysis of data from seven randomised controlled trials demonstrated a higher risk of AEs of hypocalcaemia among denosumab versus control groups [23] . Our analysis included laboratory events of hypocalcaemia using patient-level data from three identically designed trials, including non-symptomatic events.
Osteoclast inhibition rarely results in clinically important declines in blood calcium in healthy individuals [24] . Clinically meaningful hypocalcaemia during antiresorptive therapy is typically associated with inadequate vitamin D intake; insufficient calcium intake; impaired renal function; hypoparathyroidism; or extensive osteoid due to high bone turnover, osteomalacia, rapid skeletal growth, or Paget disease [25] [26] [27] [28] . In our analysis, denosumab-treated patients who developed hypocalcaemia had higher baseline uNTx levels and median baseline BSAP levels twice as high as those who did not. Elevated BSAP levels may indicate potential calcium deposition in osteoid and undermineralised bone matrix, a phenomenon that can persist for weeks or months after osteoclast inhibition. These results suggest that patients with high bone turnover may be more susceptible to hypocalcaemia when osteoclasts are inhibited, particularly when calcium and vitamin D intake is insufficient. This observation corroborates the importance of calcium and vitamin D intake in compensating for antiresorptive-mediated reductions in bone resorption.
Hypocalcaemia incidence with denosumab was lower in patients with normal baseline creatinine clearance levels, consistent with the kidney's role in compensating for decreased skeletal calcium mobilisation. Osteoclast inhibition via denosumab typically leads to increased parathyroid hormone (PTH) release [29] , and functionally impaired kidneys may be less effective at producing active vitamin D (1,25(OH) 2 D 3 ; calcitriol) in response to this PTH signal. Serum calcitriol was not measured in these studies, but impaired renal production of calcitriol could diminish intestinal calcium absorption, leading to increased risk of hypocalcaemia with antiresorptive therapy. In this analysis, treatment with ZA in patients with the lowest levels of creatinine clearance had a similar subject incidence of hypocalcaemia compared with those with normal creatinine clearance. This could be explained by the downward dose adjustment of ZA in patients with impaired renal function (in 18% of patients) [5] , which may have mitigated hypocalcaemia incidence.
Our findings suggest a potentially important contribution of osteoid as a risk factor for hypocalcaemia. Hypocalcaemia was most common in patients with prostate cancer, in whom skeletal metastases often produce newly formed bone and mineralising osteoid, which can continue to absorb extracellular calcium after osteoclastic activity is inhibited. Recent preclinical data indicate that calcium absorption by osteoid plays an important role in serum calcium reductions after osteoclasts are inhibited by denosumab [30] . Furthermore, across all tumour types, the risk of hypocalcaemia was greatest during the first 6 months after initiating denosumab. Denosumab maximally decreases bone resorption markers within 2 weeks, whereas bone formation markers reach maximal reductions after 3-6 months [21, 31, 32] . Thus, although denosumab rapidly decreases skeletal calcium release, the newly formed undermineralised matrix may continue to absorb extracellular calcium for several weeks or months [31] . The rate of occurrence of hypocalcaemia in the current study was lower and generally stable beyond 6 months after initiating denosumab, consistent with the predicted closure and mineralisation of the remodeling space [33] .
It is unlikely that hypocalcaemia in clinical practice persists for as long as suggested in our analysis [34] . Frequent measurements used in clinical practice to monitor for resolution of hypocalcaemia were not required or reported in these trials; thus, resolution may have occurred between study visits but was not detected until the next study-directed visit.
In summary, hypocalcaemia is a known risk associated with antiresorptive therapies, including denosumab 120 mg. It is important to correct hypocalcaemia, or any potential vitamin D deficiency, before initiating denosumab or another antiresorptive agent, particularly in patients exhibiting factors associated with increased risk (prostate cancer or SCLC, reduced creatinine clearance and higher baseline values of uNTx and BSAP). Hypocalcaemia associated with antiresorptive therapies may be prevented by counseling patients on the importance of adequate calcium and vitamin D intake, advising them of the pertinent symptoms of hypocalcaemia, and monitoring of serum calcium levels, particularly within the first weeks, during therapy. Hypocalcaemia occurring in this setting should be appropriately managed, including administration of intravenous calcium if required. With proactive and careful monitoring, hypocalcaemia is preventable and effectively manageable when manifested.
